Quick Answer
IRONWOOD PHARMACEUTICALS INC reported Research And Development Expense of $95.14 million for the year ending 2025.
- IRONWOOD PHARMACEUTICALS INC showed a decrease of -14.6% in Research And Development Expense from 2024 to 2025.
- This data is from IRONWOOD PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $19.90 million | Q3 2010: $18.74 million | Q1 2011: $19.56 million | Q2 2011: $19.41 million | Q3 2011: $22.91 million | Q1 2012: $29.51 million | Q2 2012: $32.24 million | Q3 2012: $23.45 million | Q1 2013: $32.75 million | Q2 2013: $24.09 million | Q3 2013: $23.02 million | Q1 2014: $27.14 million | Q2 2014: $22.14 million | Q3 2014: $25.12 million | Q1 2015: $26.64 million | Q2 2015: $28.65 million | Q3 2015: $25.83 million | Q1 2016: $31.84 million | Q2 2016: $31.68 million | Q3 2016: $37.53 million | Q1 2017: $33.70 million | Q2 2017: $37.34 million | Q3 2017: $37.07 million | Q1 2018: $36.51 million | Q2 2018: $23.19 million | Q3 2018: $29.16 million | Q1 2019: $32.20 million | Q2 2019: $28.76 million | Q3 2019: $27.55 million | Q1 2020: $28.03 million | Q2 2020: $22.08 million | Q3 2020: $21.69 million | Q1 2021: $15.48 million | Q2 2021: $12.16 million | Q3 2021: $10.91 million | Q1 2022: $10.82 million | Q2 2022: $11.45 million | Q3 2022: $11.55 million | Q1 2023: $12.85 million | Q2 2023: $34.58 million | Q3 2023: $32.99 million | Q1 2024: $25.82 million | Q2 2024: $30.39 million | Q3 2024: $29.83 million | Q1 2025: $27.43 million | Q2 2025: $23.37 million | Q3 2025: $22.47 million.
- Over the full 17 years of available data (2009 to 2025), IRONWOOD PHARMACEUTICALS INC's Research And Development Expense has grown by 25.0%.
- Historical annual values: Fiscal year 2025: $95.14 million | Fiscal year 2024: $111.42 million | Fiscal year 2023: $116.09 million | Fiscal year 2022: $44.27 million | Fiscal year 2021: $70.41 million | Fiscal year 2020: $88.06 million | Fiscal year 2019: $115.04 million | Fiscal year 2018: $101.06 million | Fiscal year 2017: $88.15 million | Fiscal year 2016: $139.49 million | Fiscal year 2015: $108.75 million | Fiscal year 2014: $101.89 million | Fiscal year 2013: $102.38 million | Fiscal year 2012: $113.47 million | Fiscal year 2011: $86.09 million | Fiscal year 2010: $77.45 million | Fiscal year 2009: $76.10 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: